Bexsero Dose Reminder

Thank you for signing up to receive a reminder for when your child is due to receive their next BEXSERO dose! You will receive an email shortly confirming your registration.

Thank you for signing up to receive a reminder for when your child is due to receive their next BEXSERO dose! You will be sent a confirmation text message. You must reply with YES to the text to confirm your enrolment.

Thank you for signing up to receive a reminder for when your child is due to receive their next BEXSERO dose! You will receive an email shortly confirming your registration and you will also be sent a confirmation text message. You must reply with YES to the text to confirm your enrolment.

Infants aged 2 through 5 months (2 doses + 1 booster)*^†

Your child should receive a primary course of 2 doses of the vaccine followed by a third (booster) dose. The interval between vaccinations should be at least 2 months. A third (booster) vaccination is required in the second year of life after an interval of at least 6 months from the last injection of the initial course.

* The initial course can also be given as 3 injections with ≥1 month interval between the primary doses. A booster dose should be given in the 2nd year of life after an interval of ≥6 months from the last injection of the initial course.

† The need for, and timing of, further doses has not yet been determined.

Infants aged 6 through 11 months

Your child should receive 2 primary doses, given at least 2 months apart. A 3^rd booster dose is required in the second year of life after an interval of at least 2 months from the last dose.

Children* aged 12 through 23 months

Your child should receive 2 primary doses, given at least 2 months apart. A 3^rd booster dose is required after an interval of 12 to 23 months from the second injection.

Children, adolescents, or adults aged 2 through 25 years

Individuals should receive 2 doses, given at least 1 month apart. An additional booster injection may be considered in individuals at continuous risk of exposure to meningococcal disease.

BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed) is a vaccine for the prevention of invasive meningococcal group B disease caused by Neisseria meningitidis group B bacteria (germs). These germs can cause invasive meningococcal group B disease (also known as Meningitis B) which can lead to serious, and sometimes life-threatening, infections such as meningitis (infection of the lining of the brain and spinal cord) and sepsis (blood poisoning). BEXSERO is given to individuals from 2 months through 25 years of age. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. BEXSERO does not treat or reduce the consequences of meningococcal meningitis, including meningitis, sepsis, and death. Ask your healthcare professional if BEXSERO is right for your child. Full product information can be found at http://gsk.ca/bexsero/en. To report an adverse event, please call 1-800-387-7374.

For information about how GSK uses, shares, and protects personal information, including information collected online, please read GSK's Privacy Statement.

Please note: This site does not provide medical advice. The contents of this site are for information purposes only and are not in any way intended to replace or substitute the advice of your healthcare professional. Your healthcare professional is the best source of information regarding your health. This digital channel is not intended as a means for reporting an adverse event (side effect) or complaint for any GlaxoSmithKline product. To report an adverse event or product complaint, please call 1-800-387-7374. This site is intended for use by Canadian residents only.

10287
07/23

How are you tracking your family’s vaccination records? Download a digital tool here